JP6077857B2 - β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法 - Google Patents

β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法 Download PDF

Info

Publication number
JP6077857B2
JP6077857B2 JP2012544948A JP2012544948A JP6077857B2 JP 6077857 B2 JP6077857 B2 JP 6077857B2 JP 2012544948 A JP2012544948 A JP 2012544948A JP 2012544948 A JP2012544948 A JP 2012544948A JP 6077857 B2 JP6077857 B2 JP 6077857B2
Authority
JP
Japan
Prior art keywords
hmb
muscle
acid
cahmb
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012544948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515009A (ja
JP2013515009A5 (enExample
Inventor
ラスメイチャー，ジョン
フラー，ジョン
ベイアー，ショーン
ニッセン，スティーヴ
アブムラド，ナジ
Original Assignee
メタボリック・テクノロジーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボリック・テクノロジーズ，インコーポレーテッド filed Critical メタボリック・テクノロジーズ，インコーポレーテッド
Publication of JP2013515009A publication Critical patent/JP2013515009A/ja
Publication of JP2013515009A5 publication Critical patent/JP2013515009A5/ja
Application granted granted Critical
Publication of JP6077857B2 publication Critical patent/JP6077857B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012544948A 2009-12-18 2010-12-20 β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法 Active JP6077857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28785709P 2009-12-18 2009-12-18
US61/287,857 2009-12-18
PCT/US2010/061367 WO2011075741A1 (en) 2009-12-18 2010-12-20 Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015188107A Division JP2016026181A (ja) 2009-12-18 2015-09-25 β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法

Publications (3)

Publication Number Publication Date
JP2013515009A JP2013515009A (ja) 2013-05-02
JP2013515009A5 JP2013515009A5 (enExample) 2013-09-26
JP6077857B2 true JP6077857B2 (ja) 2017-02-08

Family

ID=44167737

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012544948A Active JP6077857B2 (ja) 2009-12-18 2010-12-20 β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法
JP2015188107A Pending JP2016026181A (ja) 2009-12-18 2015-09-25 β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015188107A Pending JP2016026181A (ja) 2009-12-18 2015-09-25 β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法

Country Status (11)

Country Link
US (1) US20120053240A1 (enExample)
EP (1) EP2512236B1 (enExample)
JP (2) JP6077857B2 (enExample)
CN (1) CN102762097B (enExample)
CA (1) CA2784836C (enExample)
DK (1) DK2512236T3 (enExample)
ES (1) ES2608483T3 (enExample)
HU (1) HUE032486T2 (enExample)
PL (1) PL2512236T3 (enExample)
PT (1) PT2512236T (enExample)
WO (1) WO2011075741A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500198A1 (en) * 2011-07-15 2017-02-10 Nusirt Sciences Inc Compositions and methods for modulating metabolic pathways
AU2013312113B2 (en) * 2012-09-10 2018-08-02 Metabolic Technologies, LLC Composition of HMB and ATP and methods of use
HK1220391A1 (zh) 2013-03-14 2017-05-05 Abbott Laboratories 与长期体力活动不足有关的胰岛素抗性的治疗
US20140272000A1 (en) * 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
EP2993994A4 (en) * 2013-03-14 2016-11-23 Metabolic Technologies Inc LIQUIDS AND FOODS WITH BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) IN A FREE ACID FORM
AU2014386220B2 (en) * 2013-03-14 2018-04-26 Metabolic Technologies, Inc. Liquids and foodstuffs containing beta-hydroxy-beta-methylbutyrate (HMB) in free acid form
BR112015022757A2 (pt) * 2013-03-15 2017-07-18 Abbott Lab composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, fosfopeptídeo de caseína, e proteína
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
US10188611B2 (en) * 2013-12-18 2019-01-29 Capsugel Belguim NV Stable liquid filled hard capsule comprising beta-hydroxy-beta methylbutyric acid
WO2015105981A2 (en) * 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
WO2015116714A1 (en) 2014-01-28 2015-08-06 The Methodist Hospital Single-cell pipette assembly comprising single-cell pipette handle and single-cell pipette tip
JP6309287B2 (ja) * 2014-01-29 2018-04-11 協和発酵バイオ株式会社 ３−ヒドロキシ−３−メチル酪酸カルシウム含有飲料
US20160184248A1 (en) * 2014-12-15 2016-06-30 University Of Central Florida Research Foundation Inc. Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
US20160346238A1 (en) * 2015-06-01 2016-12-01 Metabolic Technologies, Inc. Compositions and Methods of Use of -hydroxy--methylbutyrate (HMB) for Decreasing Fat Mass
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
PL3349745T3 (pl) 2015-09-16 2024-05-20 Metabolic Technologies, LLC Kompozycje i sposoby stosowania beta-hydroksy-beta-metylomaślanu (hmb) w celu poprawy regeneracji po urazach tkanek miękkich
US20170127673A1 (en) 2015-11-10 2017-05-11 Metabolic Technologies, Inc. Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) as an animal feed additive
MX386153B (es) * 2016-01-13 2025-03-18 Metabolic Tech Inc COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA ESTABILIDAD DE ARTICULACIÓN.
BR112018014920A2 (en) 2016-01-21 2018-12-18 Metabolic Technologies, Inc. methods of modulating autophagy, treating or reducing the likelihood of onset of an autophagy-mediated condition, treating, inhibiting, reducing, decreasing, or preventing an age-related disorder, modulating the expression or activity of at least one factor transcription, treatment, prevention, reduction, inhibition or reduction of a pathological condition attributable to a state of nutrient excess, promoting longevity by modulating autophagy, increasing the length of time a mammal can lead a lifestyle active without suffering from conditions associated with aging and extending the health of a mammal.
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
EP3463327B1 (en) * 2016-05-25 2024-04-17 TSI Group Co., Ltd. Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
PL3528801T3 (pl) 2016-10-21 2025-02-03 Metabolic Technologies, LLC Kompozycje i sposoby zastosowania beta-hydroksy-beta-metylomaślanu (hmb) i probiotyków
US12370159B2 (en) * 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
JP7022420B2 (ja) * 2017-06-30 2022-02-18 株式会社東洋新薬 経口組成物
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
MX2020007008A (es) * 2018-01-05 2021-04-28 Texas Tech Univ Office Of Research Commercialization COMPOSICIONES Y MÉTODOS DE USO DE ß- HIDROXI-ß-METILBUTIRATO (HMB) ASOCIADO CON AYUNO INTERMITENTE.
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10888576B2 (en) 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12186297B2 (en) * 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US20010008641A1 (en) * 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
EP1429602B1 (en) * 2001-08-31 2009-12-16 Rutgers, The State University Of New Jersey Methods for treating disorders using plant extracts
DE10215007A1 (de) * 2002-04-05 2003-10-16 Degussa Bioactives Deutschland Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
EP1750527A1 (en) * 2004-03-11 2007-02-14 Wiley Organics, Inc. Compositions and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
EP2381784B1 (en) * 2008-12-09 2018-07-11 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤

Also Published As

Publication number Publication date
JP2013515009A (ja) 2013-05-02
EP2512236A4 (en) 2013-06-19
PT2512236T (pt) 2016-12-29
HUE032486T2 (en) 2018-05-02
PL2512236T3 (pl) 2017-06-30
JP2016026181A (ja) 2016-02-12
WO2011075741A1 (en) 2011-06-23
CN102762097B (zh) 2015-06-17
US20120053240A1 (en) 2012-03-01
EP2512236A1 (en) 2012-10-24
CN102762097A (zh) 2012-10-31
EP2512236B1 (en) 2016-10-19
CA2784836A1 (en) 2011-06-23
CA2784836C (en) 2019-08-20
ES2608483T3 (es) 2017-04-11
DK2512236T3 (en) 2017-01-16

Similar Documents

Publication Publication Date Title
JP6077857B2 (ja) β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法
AU2014236004B2 (en) Compositions and methods for producing elevated and sustained ketosis
US6031000A (en) Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
EP2097082A1 (en) Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis
JP6858714B2 (ja) 脂肪量を低減するためのβ−ヒドロキシ−β−メチルブチレート（ＨＭＢ）の組成物および使用方法
EP2057905A1 (en) Composition for moderating Triglyceride and Cholesterol Levels
JP4767542B2 (ja) 男性更年期が原因の異常の予防および／または治療のためのカルニチンの使用
US20160184248A1 (en) Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
US20210113501A1 (en) Method of administering beta-hydroxy-beta-methylbutyrate (hmb)
WO2006017590A2 (en) Use of methyl pyruvate for the purpose of reducing weight gain in mammals
HK1170632A (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
HK1170632B (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
JP2000302677A (ja) カルニチン自己産生能改善作用を有する医薬および食品・飼料組成物
US20250120425A1 (en) Combinations of Ketogenic Supplements for Rapid and Sustained Blood Ketone Levels in Dieters and Patients
JP2023530485A (ja) 運動なしで、筋量、筋力および筋機能を改善するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用法
HK1216847B (zh) 用於产生升高和持久的酮症的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151104

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170113

R150 Certificate of patent or registration of utility model

Ref document number: 6077857

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250